NCT05248776View on ClinicalTrials.gov

Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes

PHASE2UnknownINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Type 2 Diabetes

Interventions

DRUG

CPL207280

IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).

DRUG

Placebo

Matching placebo tablet.

Trial Locations (1)

05-830

RECRUITING

BioResearch, Kajetany

Sponsors

Lead Sponsor

Celon Pharma SA

All Listed Sponsors

collaborator

National Center for Research and Development, Poland

OTHER

lead

Celon Pharma SA

INDUSTRY